The effect of 5-azacytidine on erythroid precursors and progenitors was studied in nine patients with sickle cell anemia or severe thalassemia. Each patient received the drug intravenously for 5 or 7 d. 5-Azacytidine caused a four-to sixfold increase in y-messenger RNA concentration in bone marrow cells of eight of the nine patients and decreased the methylation frequency of a specific cytosine residue in the
Introduction
The severe hemoglobinopathies or fl-thalassemias reflect alterations in the structure or function of the fl-globin gene, respectively. The onset of these genetic disorders of hemoglobin occur after the perinatal switch from fetal hemoglobin (HbF)' y-globin synthesis. Reactivation of the globin genes with replacement of the defective 13s chain, or as compensation for deficient 3-synthesis, could be effective treatment for sickle cell anemia or the fl-thalassemias. Normal humans produce a low level of HbF after the first year of life. Usually <1% of the total hemoglobin is HbF and it is restricted to a small proportion of the total erythrocytes called F-cells (1) . The formation of F-cells appears to be modulated during both erythroid precursor and progenitor development. There is asynchronous synthesis of HbF and HbA during erythroblast maturation; fetal hemoglobin is produced predominantly in the early pro-and basophilic erythroblasts (2) (3) (4) . Erythroid progenitors from adult bone marrow form colonies of erythroblasts containing substantially more HbF than is found in vivo (5) . The erythroid colonies produced in culture from progenitors of a single individual produce highly variable amounts of HbF (6) (7) (8) (9) . This evidence that modulation of HbF synthesis also occurs during progenitor differentiation, and the clinical observation that HbF synthesis increases transiently after bone marrow transplantation or recovery from erythroblastopenia (10, 11) suggests that HbF synthesis might be reactivated with appropriate stimuli in patients with mutations in the fl-globin genes.
Several molecular correlates of hemoglobin switching have been defined. Regulation appears to occur at the level of gene transcription (12) . There are changes in chromatin structure as reflected by the disappearance of nuclease-sensitive sites immediately upstream from the y-globin genes when these genes are switched off during development (13) . The cytosine residues in this region are relatively undermethylated during 'y-gene expression in the fetus but become fully methylated in adult bone marrow, where the y-globin genes are repressed (14). The latter observation prompted the use of 5-azacytidine, a cytosine analogue that inhibits the enzymatic methylation of newly synthesized DNA, in an effort to activate the globin genes, first in experimental animals (15) and later in humans (16) (17) (18) .
Administration of 5-azacytidine led to a nearly complete switch from adult to fetal hemoglobin synthesis in baboons and a substantial increase in HbF synthesis in humans. This increase in HbF production was accompanied by improved production of erythrocytes in thalassemic patients ( 16) and by a reduction in sickling propensity of the erythrocytes in patients with sickle cell anemia (17) . Reduced methylation upstream from the y-gene accompanied the increase in yglobin gene expression (16) (17) (18) . Although the reduction in methylation was a global effect in that many cytosine residues showed decreased methylation frequency, only the y-globin gene among several genes assayed showed a significant increase in expression.
This unexplained specificity, together with the known cytotoxic effects of the drug, suggested a mechanism of action for 5-azacytidine independent of its direct effects on DNA methylation. Recent experimental studies in baboons have shown that 5-azacytidine is cytotoxic to progenitors, leading to the hypothesis that the increase in HbF production occurs in part due to regeneration from earlier erythroid progenitors with a higher likelihood of forming erythroblasts that make HbF (19) . That hydroxyurea, a cytotoxic drug with no known direct effects on DNA methylation, increases HbF synthesis in anemic monkeys has been interpreted as supporting this type of mechanism (20).
Our studies on the effect of 5-azacytidine in humans have included a detailed examination of the effect of this drug on erythroid progenitors and precursors. In this paper we describe the cellular and molecular data obtained from the study of nine patients, and these results are correlated with the clinical response of each individual patient. The results imply a complex mechanism of action but suggest that the response to 5-azacytidine is at least in part due to a direct noncytotoxic effect of the drug on erythroid precursors and progenitors.
Methods

Characteristics ofpatients studied
Nine patients were studied in detail. Each was over the age of 21 yr and had either sickle cell anemia or severe (homozygous) (l-thalassemia (Table I) . Detailed clinical descriptions of patients 1-5 have been previously published (16, 17) . Patients 6-9 had a severe sickle syndrome with incapacitating chronic pain, intermittent acute pain crisis, and a significant transfusional iron burden with secondary hemochromatosis. Limited data are also presented on three additional patients with sickle cell anemia treated at Johns Hopkins Hospital, Baltimore, MD; their clinical features have been (18, 21) , or will be, described in detail elsewhere. The protocol for drug administration was approved by the National Heart, Lung, and Blood Institute Review Board and informed consent was obtained. Two treatment regimens were used. Patients treated with regimen A received 5-azacytidine (2 mg/kg per d) by continuous infusion for 7 d as described previously (16, 17) . Patients treated with regimen B received a single, daily intravenous infusion of 5-azacytidine (1.5 mg/kg per d) over 8 h for 5 successive days. Three patients treated at Johns Hopkins Hospital received 2 mg/kg per d given in divided doses intravenously at 8-h intervals (regimen C). Several patients experienced mild to moderate nausea and vomiting which was controlled with antiemetics, but no other significant side effects were observed.
After informed consent was obtained, hematologically normal volunteers donated bone marrow for various in vitro studies. A protocol for obtaining bone marrow from normal individuals was approved by the National Heart, Lung, and Blood Institute Review Board.
DNA and RNA analysis RNA and DNA were recovered from bone marrow cells after lysis in guanadinium HCI/sarcosyl as previously described (22). RNA was analyzed with SI mapping (23) or primer extension techniques (24) . For SI mapping, total bone marrow RNA was annealed to uniformly radiolabeled DNA probes prepared on single stranded templates of M13mp7-'y or fl-globin gene recombinants as previously described (25) . Hybridization and SI digestion conditions followed published protocols (23). After SI nuclease digestion, samples were precipitated with ethanol, heat denatured, and analyzed on 8% polyacrylamide sequencing gels with subsequent autoradiography (26) . a-globin mRNA was analyzed by primer extension by use of an oligonucleotide primer (P-L Biochemicals, Inc., Milwaukee, WI) corresponding to nucleotides 97 through 115 3' to the cap site. The primer was 5'-labeled by the use of polynucleotide kinase and purified by published techniques (27) .
The radiolabeled probe and RNA were coprecipitated and Iyophilized.
After primer extension with reverse transcriptase, extended products were resolved on 8% polyacrylamide sequencing gels. Densitometric analysis of radiographs provided a quantitative estimate of relative mRNA concentrations.
The frequency of cytosine methylation near the y-globin genes was ascertained by restriction enzyme analysis. Total bone marrow DNA was first digested to completion with the enzyme Eco RI and then further digested with a fivefold excess of the enzyme HpaII (14, 16, 17) . The latter enzyme cleaves only if the internal cytosine of the DNA sequence recognized by HpaII [CCGG] is unmethylated. Restriction enzymes were obtained from Bethesda Research Labortories (Gaithersburg, MD) and used according to the manufacturer's recommendations. Completeness of digestion was determined by standard techniques. After double digestion, samples were electrophoresed on 1% agarose vertical slab gels and DNA was transferred to nitrocellulose filters by the technique of Southern (28). Filters were baked, prehybridized, and washed as previously described (29) . Filters were then autoradiographed at -70°C by the use of intensifying screens.
Analysis ofHbF
Total HbF. HbF in peripheral blood was determined from the percentage in hemolysates as measured by alkaline denaturation (30) and reference to total hemoglobin levels.
F-reticulocytes. Reticulocytes containing HbF were defined by microscopic immunoprecipitate reactions by use of rabbit anti-human HbF antibody as described in detail elsewhere (31 Co., St. Louis, Missouri); 100 U/ml penicillin/streptomycin (MA Bioproducts, Walkerville, Maryland); 2.5 U/ml of erythropoietin (Connaught Laboratories, Willowdale, Ontario), and 10% phytohemagglutinin (Gibco Laboratories, Grand Island, New York) stimulated leukocyteconditioned media. Cultures were incubated at 370C in 95% humidity and 5% CO2. Erythroid progenitor types were assayed by their distinctive colony-forming characteristics as follows: colonies derived from the late erythroid progenitor (CFU-E) were counted on day 8 and characterized by a'single cluster of well-hemoglobinized cells; colonies derived from more primitive erythroid progenitors, burst-forming units (BFU-E), were scored on day 18 and characterized as consisting of three or more clusters of well-hemoglobinized cells (32) . In our laboratory the number of colonies in cultures of I05 normal bone marrow mononuclear cells is as follows: CFU-E derived, 93+11, and BFU-E derived, 104±11
(mean±SEM, n = 22).
For determinatiQn of HbF content of individual erythroid cells contained in erythroid colonies, mature well-hemoglobinized colonies were plucked on day 8 (CFU-E derived colonies) or day 18 (BFU-E derived colonies) under microscopic visualization by use of a tapered Pasteur pipette. Analysis of BFU-E derived colonies was restricted to those derived from the most primitive progenitors by plucking of only those colonies consisting of > 16 clusters (32) . Approximately 50 CFU-E derived colonies or 5-10 primitive BFU-E derived colonies were pooled, gently resuspended, and washed in buffered saline, and HbF was measured as described above.
In vitro treatment with 5-azacytidine. Bone marrow mononuclear cells from normal volunteers, separated by Percoll density sedimentation, were added at a final concentration of 2 X 106 cells/ml to liquid cultures containing 5-azacytidine at concentrations from 0.1 to 10 Uzg/ ml in 30% FCS, 1% BSA, 10-4 M ,B-mercaptoethanol without erythropoietin, or 10% phytohemagglutinin-stimulated leukocyte-conditioned medium in IMDM at 37°C. To maintain 5-azacytidine concentrations, additional 5-azacytidine was added 8 and 16 h after initiation of incubation. After 24 h, cells were washed and replated in standard methylcellulose culture (see above) at 1 X 101 cells/ml in the absence of 5-azacytidine. CFIJ-E derived colonies were scored 8 d later. The HbF content of individual erythroblasts in these colonies was determined by radial immunodiffusion as described above. Fig. 1 A were derived from an analyses of bone marrow samples obtained from patient 7 on day 0, 2, or 7. Relative to the pretreatment day 0 value, y-mRNA content was increased 1.4-fold on day 2 and 5.9-fold on day 7 as determined by demisometric analyses of the radioautographs. An increase in y-mRNA content was documented on day 2 in three patients studied and on day 7 in all patients (data not shown), with the exception of patient 9. For this patient, during the first course of treatment, there was a small increase in y-mRNA content (1.5X) on day 7 as compared with control obtained on day 0, but there was no detectable increase in y-mRNA content during the second course on day 3 as compared with the day 0 bone marrow RNA sample (Fig. 1 B) (Fig. 4, A Each RNA sample was analyzed in replicate by hybridization to either primer the 7-specific probe or the a-specific probe followed by SI nuclease or primer extension, respectively. Radiolabeled products were resolved on separate sequencing gels with subsequent autoradiography. The results obtained for the a-specific probe are shown directly below the corresponding lanes of the y-specific probe. (B) Response of patient 9. For this patient, total bone marrow RNA was simultaneously assessed for a-and #-globin mRNA by annealing RNA samples to a mixture of the 7-specific probe as described in A and a a-specific probe spanning the 5' end of the gene as depicted in the lower part of the figure. The day on which the bone marrow was taken and the amount of RNA used in the hybridization are indicated at the top of each lane. After SI nuclease treatment, samples were analyzed on sequencing gels with subsequent autoradiography.
Results
Molecular
obtained by study of patients who received the bolus infusions (Fig. 4, C and D) . Of the six patients whose marrow was assayed on day 2 of treatment, only one showed a modest decrease of 30% in CFU-E as compared with the pretreatment value, whereas the remainder showed stable or even increased values (0-65%). Two additional patients, for whom no data was available from day 2, were found to have a striking increase in colony numbers in bone marrow samples cultured on day 7. Cytotoxicity to the progenitor compartment (as reflected by a decrease in CFU-E derived colonies) was evident by day 7 or later for five patients. The variablility in colony formation among six normal individuals (each studied 2 or 3 times) expressed as an average standard deviation of the means was 13.3 with a range of 42-162 CFU-E derived colonies/105 bone marrow mononuclear cells. Thus, we believe that the changes observed during and after treatment are not due to random variation between samples.
Detailed analyses of HbF content in erythroblasts derived from erythroid progenitors in vitro were obtained for three patients who showed an increase in CFU-E numbers on either day 2 (patients 7 and 8) or day 7 (patient 5) of the treatment course. Well-hemoglobinized colonies derived from mature progenitors were identified and plucked from cultures on the eighth day in vitro and pooled, and the HbF content of individual erythroblasts was determined by radial immunodiffusion. These data are presented in Fig. 5 as plots of the cumulative frequency of erythroblasts containing different amounts of HbF. By day 2 of treatment, two patients (Fig. 5,  A and B) , and by day 7 of treatment, all three patients studied,
showed an increase in HbF content in CFU-E derived erythroblasts, as reflected by a shift in the cumulative frequency plot to the right and by an increase in the mean HbF content per erythroblast. These data show that in vivo exposure of bone marrow to 5-azacytidine for 2 or 7 d yields CFU-E progenitors whose phenotype is demonstrably altered; erythroblasts generated in vitro from these progenitors contain increased amounts of HbF in the absence of further exposure to 5-azacytidine.
In four of the seven patients, the number of colonies derived from BFU-E remained constant or increased during or after the 5-azacytidine treatment course, whereas in three patients a decrease in BFU-E derived colonies was evident in one or more bone marrow samples subsequent to treatment (Fig. 4) . One of the two patients (number 7) whose CFU-E derived erythroblasts from day 2 marrow contained increased amounts of HbF also had an increase in HbF in BFU-E derived colonies from the day 2 sample (mean day 0, 12.94 pg vs. mean day 2, 25.6 pg). In others the base-line HbF in BFU-E colonies was high, preventing meaningful analyses.
Manipulation ofprogenitors with 5- we examined the effects of exposing progenitors to 5-azacytidine in vitro. Fig. 6 shows the effect on CFU-E derived colony numbers of exposing bone marrow cells from normal volunteers to Table I ). shown). Based on these results, bone marrow cells from two normal volunteers were exposed to nontoxic concentrations of 5-azacytidine for 24 h before plating in methylcellulose culture in the absence of 5-azacytidine was done. In colonies derived from the CFU-E of both individuals, there was an increase in the percentage of HbF containing erythroblasts at doses of 5-azacytidine that did not significantly reduce colony number (Table III) . At higher concentrations a statistically significant increase in HbF per erythroblast was also observed for the colonies derived from bone marrow cells of both individuals, although in one case (experiment 2) this was accompanied by a substantial reduction in colony number (Table III) .
Correlation of the effect of5-azacytidine on erythropoiesis with the clinical response in individual patients Good responders. 5-Azacytidine caused a progressive increase in HbF concentration and an increase in the total hemoglobin concentration in several patients. Such a response has previously been described in patients 1-5 (13, 14) ; the clinical course of two additional patients (8 and 7) is shown in Fig. 7 . These two patients who have sickle cell anemia had a prompt increase in the absolute F-reticulocyte count, an increase in the nucleated erythrocyte count, and a documented increase in mRNA content in bone marrow erythroblasts during and after 5- azacytidine administration. The concentration of bone marrow erythroid progenitors that formed colonies remained stable (e.g., patient 8, Fig. 7) or increased (e.g., patient 7, Fig. 7 ) by day 2 of treatment and there was a documented increase in HbF in these colonies as compared with control colonies (Fig. 5) .
Certain patients who exhibit the clinical response described above nonetheless show a decrease in colony numbers by day (patients 2 and 7). In one case this decrease in colony numbers was found to correlate with a fall in reticulocyte count as described for patient 2 previously. Relevant data are not available for patient 7. Moderate responders. Patient 6 represents a different pattern of response. This patient exhibited a striking increase in absolute F-reticulocytes that was accompanied by a progressive rise in the HbF concentration in blood to approximately six times higher than the pretreatment level but not by a rise in total hemoglobin (Fig. 8) . The increase in HbF concentration in blood between days 5 and 15 did not result in a significant increase in total hemoglobin concentration. Apparently the magnitude of the increase in HbF was compromised by a rebound absolute reticulocytosis and a fall in the absolute Freticulocyte count between days 9 and 14. These in vivo results correlated with the in vitro culture data. As compared with the day 0 sample, the number of mature progenitors (CFU-E) that formed colonies had increased twofold in the day 7 sample, consistent with rebound absolute reticulocytosis. The erythroblasts derived from these progenitors in vitro showed no increase in HbF content as compared with control (Fig. 9) .
Nonresponder. Finally, one patient (number 9) had no significant increase in HbF concentration after treatment; this patient's hemoglobin concentration fell after treatment regimen B (Fig. 10) . He was treated a second time with regimen A, which was previously found to be effective in patients 1-5. Serial measurement of F-reticulocytes were made and the behavior of progenitors before and after initiation of 5-azacytidine was determined. Only a very modest increase in HbF concentration was found in peripheral blood; this increase occurred several days after the treatment course was completed (Fig. 10) . Toxicity to the bone marrow was reflected by a striking fall in absolute reticulocyte count. The absolute Freticulocyte count remained relatively constant, however, re- sulting in a moderate increase in the percentage of F-reticulocytes. Accordingly, this period of relative reticulocytopenia but relative increase in F-reticulocytes was followed by a' niodest increase in HbF concentration. Restoration of reticulocyte numbers to near base-line values between days 23 and 27 was not accompanied by an increase in the number of F-reticulocytes. Consistent with these findings, the HbF content of erythroblasts present in CFU-E derived colonies were identical in cultures of bone marrow obtained on day 0 and day 3; thus his progenitor cells were apparently not altered upon exposure to 5-azacytidine in vivo (Fig. 9 B) .
Of interest in this nonresponder, the base-line HbF contedt per erythroblast in his colonies was higher than that found in the colony erythroblasts of any other patient. Even though there was no clinical or in vitro evidence of an increase in HbF synthesis, a decrease in the frequency of methylation in the region of the y-globin genes was documented during both treatment periods (Fig. 2) 17.8±11.5** Figure 6 . Toxicity profile for CFU-E after exposure to 5-azacytidine I in vitro. Bone marrow cells from normal volunteers were placed in liquid culture containing 5-azacytidine at concentrations ranging = : from 0.1 to 10 ug/ml as described in Methods. Five separate experi---j ments were performed. To maintain the specified concentrations, number of burst colonies was unaffected by 5-azacytidine treatment. 6 d later (corresponding to day 12 of our treatment schedules) the number of clusters and colonies that formed in bone marrow cultures was increased over those observed in Table I ). Responses are shown for bone marrow taken before initiation of 5-azacytidine administration (day 0, ) and at day 2 (---) and/or day 7 ( ----) after the initiation of therapy. F-NRBC, percentage of nucleated erythrocytes that contain HbF. *, P < 0.05. **, P < 0.01.
The careful study of Torrealba-de Ron et al. (19) of these late progenitors from earlier progenitors were responsible, at least in part, for the augmentation in synthesis of HbF. A shift to a less mature progenitor as a source of erythroblasts and ultimately reticulocytes has also been proposed as the basis for the ability of hydroxyurea to augment HbF synthesis in anemic monkeys (Macaca fascicularis) (20). We interpret our analysis of the kinetics of the effect of 5-azacytidine on human erythroid cells as being most consistent with a direct action of 5-azacytidine on erythroblasts; moreover, a toxic or cytoreductive action on late progenitors is not necessary to achieve an increase in HbF synthesis in the erythroblasts derived from these cells. Strongly supporting a direct action are the early rise in F-reticulocytes and y-mRNA levels reported herein and in previous studies (16) (17) (18) . For example, patients 7 and 8 exhibited a two to threefold increase in the percentage of F-reticulocytes within 24-48 h of starting 5-azacytidine treatment (Fig. 4) without a significant change in total reticulocyte concentration. Ferrokinetic studies (33) and 59Fe-labeling of bone marrow cells (34) suggest a transit time from bone marrow proerythroblasts to peripheral blood reticulocytes of from 72 to 95 h. Although this interval might be shortened in the presence of hemolysis, accelerated erythropoiesis, and drug administration, it seems unlikely that reticulocyte counts could be sustained at relatively constant levels during 5-azacytidine administration by recruitment and accelerated maturation of erythroid progenitors if there were substantial killing of cells already in the erythroblast compartment. The mechanism of this early effect on the erythroblast population remains conjectural but presumably must depend on some distortion of the normal erythroid maturational kinetics.
48 h after treatment is started, hypomethylation of a CpG residue immediately upstream from the y-gene coding se- 554 Humphries, Dover, Young, Moore, Charache, Ley, and Nienhuis A depicts the results from patient 6 (see Table I ) and B depicts the results from patient 9 during his second treatment course (see Table  I ). Data are presented as cumulative frequency plots of erythroblasts containing up to a certain amount of HbF. Determinations were made on bone marrow samples obtained at the start of 5-azacytidine treatment (day 0, -) and 3 or 7 d later (..... ).
quences is demonstrable in the bone marrow cells of most patients (35) . However, the causal role of demethylation in inducing gene expression has been questioned (36, 37 An alternative mechanism by which 5-azacytidine could enhance globin production in erythroblasts relates to the known asynchronous synthesis of HbF and HbA during erythroid maturation (2-4). HbF synthesis apparently occurs mainly in pro-and basophilic erythroblasts; HbA synthesis begins slightly later in the maturation pathway but greatly exceeds HbF synthesis during the later stages of erythroblast maturation. Cell-cycle specific agents such as 5-azacytidine might alter the kinetics of cell division and delay the normal switch from HbF to HbA during cellular maturation in the erythroblast compartment. To account for the increased percentage of F-reticulocytes by this mechanism would require that drug administration also increase the proportion of erythroblasts that make HbF.
Erythroid progenitors exposed to 5-azacytidine either in vivo or in vitro yielded colonies that made more HbF than did control progenitors, even though colony formation occurred in the absence of the drug. Moreover, the number of progenitors detected was stable or even increased after short exposure to Table I ). The We cannot exclude the possibility of a rapid cytotoxic action with a rapid recovery in vivo since time points for bone marrow sampling were necessarily limited. Definitive tests of these possibilities await the availability of purified populations of erythroid progenitors where reprogramming, recruitment, and cytotoxicity can be rigorously assessed. We observed variable toxicity on the late erythroid progenitor cells in cultures of bone marrow obtained on day 7 of the treatment schedule analogous to the decrease in colony forming progenitors in bone marrows from baboons on day 6 of their treatment schedule with 5-azacytidine (19) . Evidence of cytotoxicity should not be used to infer that this is necessarily the mechanism by which the drug works. Our data seem most consistent with the interpretation that this late toxic effect is neither crucial for, nor consistent with, the kinetics of the observed increase in HbF synthesis. The direct demethylating effect of 5-azacytidine is not required since hydroxyurea (20) and arabinosylcytosine (39) also lead to increased HbF synthesis. The data seem most consistent with a recruitment model analogous to that proposed by Papayannopoulou et al. (39) although we disagree with their interpretation that significant cytoreduction is required.
The previously reported (18) increase in nucleated erythrocytes in the peripheral blood of sickle cell anemia patients between 6 and 10 d after treatment with 5-azacytidine is initiated has proven to be a consistent effect, although it does not occur in patients with thalassemia. We understand neither the mechanism of this effect nor the reason why it is restricted to those patients with sickle cell anemia. The increase in nucleated erythrocyte count follows the increase in assayable erythroid progenitors by 4-8 d. Perhaps the properties of erythroid precursors derived from the early recruited progenitors are altered in a way that allows their accelerated release from the bone marrow.
Our experience has revealed considerable heterogeneity in the clinical response to 5-azacytidine. Many patients show an early rise in F-reticulocytes and a sustained increased in 'yglobin gene expression, leading to a progressive five to sixfold increase in HbF and a steady rise in hemoglobin concentration (Fig. 7) . Other patients show only a moderate increase in gene expression and HbF concentration but little or no increase in hemoglobin concentration (Fig. 8) . In a minority of patients with sickle cell anemia, HbF containing erythrocytes do not appear to have prolonged survival as compared with non-HbF containing cells (40) , which perhaps accounts for the failure of the hemoglobin concentration to rise in some patients treated with 5-azacytidine.
One of the nine patients showed no significant increase in -y-gene expression, as assessed by enumeration of F-reticulocytes or measurement of y-mRNA concentration in bone marrow.
Selective toxicity to those cells producing only HbA resulted in a substantial fall in total reticulocytes but a constant Freticulocyte concentration led to a modest increase in HbF concentration in blood. The kinetics of this response were quite different from those of the response exhibited by patients who have a substantial increase in y-gene expression as judged by the F-reticulocyte increment and an increase in y-mRNA concentration in bone marrow (compare Fig. 7 with Fig. 10) .
5-Azacytidine appeared to hold some promise for the treatment of patients with sickle cell disease. Charache and Dover have treated three patients for extended periods and observed a persistent increase in HbF concentration and some clinical improvement (21) . A controlled trial could now be justified and would be required to determine whether significant clinical benefit could be achieved with the drug. For the present, however, use of 5-azacytidine in humans has been discontinued. This decision is based on concern about its potential carcinogenic effect and because cytosine arabinoside (39) and hydroxyurea (20) have also been shown to increase HbF synthesis. These drugs, particularly hydroxyurea, are thought to be less carcinogenic. That low doses of 5-azacytidine increase HbF synthesis without depressing the bone marrow may have important implications for the choice of dose and schedule of administration of other drugs, given in an effort to achieve a clinically useful increase in production of HbF.
